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Abstract
Background: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug
resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour
reported.
Methods: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was
representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were
calculated by logistic regression.
Results: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by
heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin,
infected with subtype B virus, and recently infected (,1 year) (p,0.001). The prevalence of TDRM was highest in MSM
(prevalence of 11.1%), followed by heterosexuals (6.6%) and IDU (5.1%, p,0.001). TDRM was predominantly ascribed to
nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6% in MSM, 3.3% in heterosexuals and 2.0% in IDU
(p = 0.001). A significant increase in resistance to non- nucleoside reverse transcriptase inhibitors (NNRTIs) and a decrease in
resistance to protease inhibitors was observed in MSM (p = 0.008 and p = 0.006, respectively), but not in heterosexual
patients (p = 0.68 and p = 0.14, respectively).
Conclusions: MSM showed to have significantly higher TDRM prevalence compared to heterosexuals and IDU. The
increasing NNRTI resistance in MSM is likely to negatively influence the therapy response of first-line therapy, as most
include NNRTI drugs.
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Introduction
Antiretroviral therapy has strongly reduced morbidity and
mortality in HIV infected individuals [1]. This use of antiretroviral
medication, however, also led to transmission of drug resistant
HIV-1. Transmission of drug resistance has important clinical
ramifications as it is associated with an increased probability for
virological failure [2]. Importantly, the problem is large, with
prevalence ranging between 10 and 15% of antiretroviral naı̈ve
patients infected with a virus carrying at least one transmitted drug
resistance associated mutation (TDRM) in Europe [3–6] and
North America [6–8].
The prevalence of TDRM is expected to be different among
different routes of transmission in Europe. Men having sex with
men (MSM) are mostly originating from resource-rich countries
where antiretroviral drugs have been available for many years.
Until the early 1990s, HIV patients received mono- or dual-
therapy with nucleoside reverse transcriptase inhibitors (NRTI).
This mono- and dual-therapy led to a rapid selection of drug
resistant viruses [9,10]. In contrast, heterosexually infected
patients in Europe are mostly immigrants from Sub-Saharan
Africa or individuals from Eastern Europe areas where the use of
antiretrovirals in this case in the form of combination antiretro-
viral therapy has been initiated more recently. These differences in
treatment history between the risk groups are reflected in several
studies showing a higher likelihood in MSM to be infected with
resistant virus compared to other risk groups [3,11,12].
While access to antiretrovirals has rapidly been scaled-up during
the past decade in Eastern Europe and Africa, TDRM remains
limited with a general prevalence of ,5% in these areas [13].
However, studies have shown that in some regions in sub-Saharan
Africa TDRM is already as high as 11.6% [14]. TDRM in Africa
is specifically associated with non-nucleoside reverse transcriptase
inhibitors (NNRTIs), which is consistent with the use of single-dose
nevirapine to prevent mother-to-child transmission and NNRTI
based combinations of antiretroviral therapy (cART) [15].
These global differences in the use of cART may have
influenced TDRM in Europe over time. Yet, there are no studies
performed which analyse time trends in the various risk groups
European-wide. We examined the prevalence of TDRM for the
individual drug classes between various HIV risk groups in Europe
and to study temporal trends of TDRM in these subgroups in a
large European surveillance programme.
Methods
Ethics statement
Ethical requirements are fulfilled according to the procedure
described in the EC contract. The procedure differs among the 32
countries in the network according to national legislation. Briefly,
for each participating hospital or collection center, approval was
obtained by the institutional medical ethical review committee.
Additionally, a written informed consent was obtained for each
patient. In countries where a mandatory surveillance system was
already established, legally no informed consent was needed. All
surveillance data were made anonymous and coded at national
level.
Study population
Our analyses included data from the SPREAD Programme.
The SPREAD programme recruited individuals newly diagnosed
with HIV-1 from September 2002 through December 2007 in 27
European countries. For each country a surveillance strategy was
defined based on the following criteria: random samples were
obtained in those countries in which there was access to more than
80% of all patients newly diagnosed. Alternatively, a pre-defined
sampling strategy was used based on the geographical and risk
group distribution of newly diagnosed individuals in countries
which did not have access to at least 80% of newly diagnosed
patients. These approaches pursuit representative sampling of
newly diagnosed patients in the participating countries. For more
details on the sampling strategy, see the previous reports of the
SPREAD Programme [3,16]. Epidemiological, clinical, and
behavioral data were collected using a standardized questionnaire
within six months of diagnosis.
A blood sample was taken for genotypic resistance testing within
six months after diagnosis. Population-based nucleotide sequenc-
ing of the reverse transcriptase and protease genes of the virus was
performed at local laboratories by means of commercially
available kits or in-house methods. TDRM was defined according
to the mutation list published for surveillance of TDRM as
recommended by the World Health Organization [17].
Seroconversion was documented in a proportion of the newly
diagnosed patients. For 882 patients, a recent infection could be
established because a last negative HIV antibody test was available
within 3 years before diagnosis. In these patients, the date of
infection was estimated as the midpoint between the date of the
last negative and first positive test. In addition, for 506 patients
primary HIV-1 infection was documented based on the clinical
symptoms reported by the treating physician. In these 506
patients, the date of the first positive (and subsequently confirmed)
HIV test was used as the estimated date of infection. Since there
are limitations to the accuracy of such estimates, the results
obtained should be interpreted with care. Patients were defined as
recently infected (n = 1236) when the duration of infection was less
than 1 year. In our analyses, we use both the total number of
recently infected patients and separately the number of recently
infected patients where seroconversion was proven by a last
negative HIV antibody test.
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Statistical analyses
The HIV-1 subtypes were determined by use of the Rega HIV-
1 subtyping tool (version 2.0, available at http://www.bioafrica.
net/subtypetool/html/) [18]. The data were analyzed using the
statistical software R (version 2.11.1). Prevalence values were
calculated with a 95% Wilson score confidence interval (CI) on the
basis of a binomial distribution. Categorical data were compared
using the chi-square test, Fisher’s exact test, or logistic regression
techniques. Continuous data were investigated by means of a
Mann-Whitney U-test or the Kruskal Wallis test.
Trends in the prevalence of TDRM were calculated by




A total of 4317 newly diagnosed HIV-1 patients were included
in the SPREAD programme from September 2002 through
December 2007. From these 4317 patients, the majority (2084,
48.3%) were MSM, followed by heterosexuals (1501, 34.8%) and
injection drug users (IDU) (355, 8.2%). The baseline character-
istics of these three risk groups are summarized in Table 1. MSM
were more often recently infected (,1 year) (43.0%) than IDU
(23.4%) and heterosexuals (13.5%) (p,0.001). Within the hetero-
sexuals and IDU risk groups, a high ratio of patients had an
unknown date of infection (85% and 73%, respectively). The
percentage of the subgroup of recently infected with proven
seroconversion by last negative HIV test was 30.7% in MSM,
23.4% in IDU, and 8.9% in heterosexuals. As expected from the
higher proportion of recent infections, MSM had a higher median
CD4 cell count (435, interquartile range (IQR) 259–585 cells/
mm3) than the corresponding CD4 values found in heterosexuals
Table 1. Characteristics of HIV infected individuals.
Characteristics Categories MSM (%) Heterosexuals (%) IDU (%) p-value
HIV patients 2084 1501 355
Origin Western Europe 1457 (69.9) 589 (39.2) 179 (50.4) ,0.001
Eastern Europe & Central Asia 378 (18.1) 253 (16.9) 145 (40.8)
Sub-Saharan Africa 10 (0.5) 451 (30.0) 4 (1.1)
Other 239 (11.5) 208 (13.9) 27 (7.6)
Baseline values Plasma HIV-RNA, median (IQR), log copies/ml 4.88 (4.3–5.4) 4.79 (4.2–5.3) 4.76 (4.2–5.3) ,0.001
CD4 cell count, median (IQR), cells/mm3 435 (259–585) 280 (110–458) 392 (197–521) ,0.001
Age, mean years (IQR) 36.1 (29–41) 37.7 (29–45) 33.2 (26–39) ,0.001
Gender Male 2070 (99.3) 765 (51.0) 269 (75.8) ,0.001
CDC stage A and B 1860 (89.3) 1148 (76.5) 277 (78.0) ,0.001
C 167 (8.0) 250 (16.7) 37 (10.4)
Subtype B 1884 (90.4) 503 (33.5) 218 (61.4) ,0.001
A 86 (4.1) 275 (18.3) 79 (22.2)
C 15 (0.7) 259 (17.3) 6 (1.7)
02_AG 22 (1.1) 158 (10.5) 5 (1.4)
G 11 (0.5) 96 (6.4) 24 (6.8)
F 10 (0.5) 54 (3.6) 2 (0.6)
others 30 (1.4) 115 (7.7) 16 (4.5)
unassigned 26 (1.2) 41 (2.7) 5 (1.4)
non-B 174 (8.3) 957 (63.8) 132 (37.2)
Duration of infection ,1 year 897 (43.0) 203 (13.5) 83 (23.4) ,0.001
1–2 years 108 (5.2) 23 (1.5) 12 (3.4)
Unknown duration 1079 (51.8) 1275 (84.9) 260 (73.2)
NOTE. Data are no. (%) of individuals, unless otherwise indicated. Characteristics describe individuals from whom a baseline HIV-1 genotypic analysis was available.
CDC, Centers for Disease Control and Prevention; IQR, interquartile ranges; MSM, men who have sex with men; IDU, injection drug users.
doi:10.1371/journal.pone.0094495.t001
Figure 1. Prevalence of TDRM by drug classes in three risk
groups. Prevalences are shown of resistance to at least one of the drug
classes (Any), nucleoside reverse transcriptase inhibitor (NRTI), non-
nucleoside reverse transcriptase inhibitor (NNRTI) and protease
inhibitor (PI) in men who have sex with men (MSM), heterosexuals
(HSX), and injection drug users (IDU). * = p,0.001 in comparison with
MSM
doi:10.1371/journal.pone.0094495.g001
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(median 280, IQR 110–458 cells/mm3) and in IDU (median 392,
IQR 197–521 cells/mm3) (p,0.0001). Furthermore, the propor-
tion originating from Western Europe was highest in MSM
(69.9%), followed by IDU (50.4%) and heterosexuals (39.2%) (p,
0.0001). In 51.0% of heterosexuals, and 75.8% of IDU, patients
were male. As previously reported [19], large differences were seen
in subtype distribution (p,0.0001). The most reported HIV
subtype in viral isolates from MSM was B (90.4%) whereas in IDU
and heterosexuals subtype B was only seen in 61.4% and 33.5%,
respectively. In IDU, the most commonly found non-B subtype
was subtype A, which was observed in 22.2%. In heterosexuals,
both subtype A (18.3%) and subtype C (17.3%) were the most
frequently observed non-B subtypes.
Genotypic resistance analysis
The prevalence of individuals with at least one TDRM in MSM
was 11.1% (95% CI: 9.9–12.6%). This was significantly higher (p
,0.001) than in heterosexuals (6.6%; 95% CI: 5.4–8.0%) and
IDU (5.1%; 95% CI: 3.2–7.9%) (Figure 1). Similarly, the
prevalence of TDRM for nucleoside reverse transcriptase inhib-
itors (NRTIs), was at least twice as high in MSM (6.6%; 95% CI:
5.6–7.8%) compared to heterosexuals (3.3%; 95% CI: 2.5–4.4%;
p,0.001) or IDUs (2.0%; 95% CI: 1.0–4.0%; p = 0.001). Most of
the NRTI TDRM were thymidine analogue mutations (TAMs) in
MSM (87.7%), in heterosexuals (70.0%) and in IDU (100%).
Also for the non-nucleoside reverse transcriptase inhibitor
(NNRTI) TDRM, the prevalence in MSM (3.8%; 95% CI: 3.1–
4.7%) was significantly higher compared to heterosexuals (1.9%;
95% CI: 1.3–2.7%; p,0.001) but not to IDU (2.8%; 95% CI: 2.3–
1.3%; p = 0.44).
Notably, the prevalence of TDR for NNRTIs was higher than
for NRTIs in IDUs, but not statistically significant. The most
prevalent NNRTI TDRM was K103N (.57% in all three risk
groups).
In the protease inhibitor drug class, no statistically significant
differences were seen between the risk groups. This may be due to
the low proportions of individuals with protease inhibitor TDRM
found in all risk groups; MSM 2.7%, heterosexuals 2.5%; IDU
1.4%). The most prevalent transmitted mutation was the L90M (.
24% in all three risk groups).
A large proportion (61%) of the heterosexuals did not originate
from Western Europe (60.8%) or North America (0.06%). Of
patients not originating from Western Europe or North America,
51.8% were from Sub-Saharan Africa. The prevalence of TDRM
in heterosexuals from Western Europe or North America was
7.8% for overall, 4.1% for NRTI, 2.0% for NNRTI and 2.5% for
protease inhibitor resistance. These prevalences did not differ
significantly from the prevalence of resistance in heterosexuals
from non-Western countries (6.0% for overall; p = 0.17, 2.9% for
NRTI; p = 0.24, 1.8% for NNRTI; p = 0.85, and 2.5% for
protease inhibitor; p = 1).
Interestingly, when individuals from outside Western Europe or
North America were excluded from the analyses, the prevalence of
TDRM remained significantly different between MSM and
heterosexuals for overall TDRM (p = 0.02), NRTI (p = 0.04) and
NNRTI (p = 0.02). When we further limited our analysis to just
those recently infected from these regions (within 1 year), we found
a TDRM prevalence of 13.1% in MSM and 6.8% in heterosexuals
(13.3% and 9.7%, respectively, in recently infected proven by a
last negative HIV test). In chronically infected patients this
prevalence was 9.6% in MSM and 8.0% in heterosexuals (10.2%
and 7.8%, respectively, in all patients without a proven
seroconversion by a last negative HIV test). The difference in
TDRM prevalence could therefore only for a small part be
explained by the difference in duration of infection between MSM
and heterosexuals.
Time trends
Trends over time were examined in MSM and heterosexuals,
but not for IDU as the numbers were too low. The prevalence of
TDRM slightly increased - but not statistically significant- over
time in the MSM group, with 10.1% in 2003 and 12.5% in 2007
(odds ratio [OR], 1.06 [95% CI, 0.97–1.15]; p = 0.19) (Figure 2A).
Conversely, the prevalence declined slightly among the hetero-
sexuals with a prevalence of 8.6% in 2003 and 4.9% in 2007 (OR,
0.89 [95% CI, 0.78–1.02]; p = 0.09) (Figure 2B). The NRTI
prevalence followed the same time trend as the overall TDRM
prevalence, with an OR of 1.07 (95% CI: 0.96–1.19; p = 0.22) in
MSM and 0.84 (95% CI: 0.69–1.01; p = 0.07) in the heterosexual
group.
In prevalence of resistance to other drug classes, different trends
were observed. Importantly, the NNRTI TDRM prevalence
increased three fold from 1.7% in 2003 to 5.0% in 2007 in MSM
(OR, 1.21 [95% CI, 1.05–1.39]; p = 0.008). For protease inhibitor
TDRM, the prevalence significantly decreased over time from
Figure 2. Prevalence of TDRM in patients diagnosed from 2002
through 2007. Prevalence of TDRM is shown for any of the drug
classes (any class), nucleoside reverse transcriptase inhibitor (NRTI), non-
nucleoside reverse transcriptase inhibitor (NNRTI) and protease
inhibitor (PI) in (A) Men having sex with men (MSM), and in (B)
heterosexuals (HSX). The p-values of the time trends are shown on the
right side of the graph.
doi:10.1371/journal.pone.0094495.g002
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4.6% in 2003 to 2.0% in 2007 (OR, 0.79 [95% CI, 0.66–0.93];
p = 0.006). This increase of NNRTI TDRM and the decrease of
protease inhibitor TDRM was not observed in the heterosexuals
(p = 0.68 and p = 0.14, respectively). Adjusting for factors signif-
icantly associated with TDRM in the univariate analyses did not
change any of the time trend effects that were found.
When splitting up heterosexuals into individuals infected in
Western Europe/North America and people infected outside these
regions, no significant time trends were found for any of the drug
classes in the heterosexuals infected in Western Europe/North
America. In the heterosexuals infected in regions outside Western
Europe and North America, TDRM decreased significantly
(p = 0.03) from 7.8% in 2003 to 3.3% in 2007. This is explained
by a significant (p = 0.02) decrease in the NRTI TDRM from
4.3% in 2003 to 1.4% in 2007 (data not shown).
Discussion
We analysed epidemiological and virological data collected over
six years from the European HIV drug resistance surveillance
program to gain further insight in the risk factors and associated
time trends of transmitted resistance in relation to the HIV risk
group. MSM have a significantly higher TDRM prevalence of
11.1% compared to 6.6% in heterosexuals and 5.1% in IDU, with
the largest difference was found for NRTI TDRM. In addition,
the prevalence of NNRTI TDRM was higher in MSM compared
to heterosexuals. The prevalence of protease inhibitor TDRM was
low in all risk groups.
Similar observations in TDRM were found in the United
Kingdom in 2004 to 2006 where MSM showed a significantly
higher prevalence compared to other risk groups [11]. Our results
are in contrast with a time trend study performed in Canada,
where a significant decrease in TDRM was observed in both
MSM and the IDU patients but not in heterosexuals [20]. The
differences with our study might be due to the sampling in earlier
years (1997–2003), the sampling of only recent infected individuals
or the smaller sample size (180) in the Canadian study.
A large proportion of HIV-infected were heterosexuals origi-
nating from regions outside Western Europe and North America,
mostly from Sub-Saharan Africa. In a large part of these regions,
access to antiretroviral drugs has only become available at a large
scale during recent years. Although transmitted resistance has
been reported, it has not developed to such high levels as seen in
resource-rich countries [21], although in Uganda and South-
Africa already higher levels of TDRM prevalence are found [14].
Of interest, if we only took into account the TDRM prevalence
in heterosexuals originating from Western Europe and North
America, TDRM was still lower than the prevalence in MSM
originating from the same regions. Therefore, the difference in
TDRM prevalence between heterosexuals and MSM could not be
fully explained by immigration from HIV infected heterosexuals
from countries with a short access to therapy. A possible
explanation for the lower TDRM prevalence in heterosexuals
from Western Europe and North America is that a large
proportion is infected by individuals originating from outside
these regions. This is supported by a model of Xiridou et al. [22]
which showed that a 53% of new HIV infections in the
Netherlands was acquired from African migrants mostly (32%)
through sexual transmission in the Netherlands.
Another explanation for the lower TDRM prevalence in
heterosexuals could be that heterosexuals enrolled in surveillance
programs are more likely to have a longer duration of their HIV
infection. We indeed observed high CD4 counts in MSM
(435 cells/mm3) and very low in heterosexuals patients
(280 cells/mm3), indicating that heterosexuals were often diag-
nosed at a late stage of their disease. Resistance mutations that are
transmitted may revert to drug sensitive virus over time in plasma
because they compromise viral replicative capacity. In that case,
the resistant virus variants can no longer be detected by population
sequencing used in our study, because this method has limitations
in the detection of minor populations [23,24]. In our study,
however, we only found a non-significantly lower TDRM
prevalence in heterosexuals from Western Europe/North America
who were recently infected (6.8%) compared to chronically
infected patients from these regions (8.0%). This discrepancy is
probably due to the low numbers of recently infected in
heterosexuals from Western Europe/North America. Another
explanation for the higher TDRM prevalence in MSM might be
that TDRM is spread from untreated patients in clusters of MSM
forming a sub-epidemic in these patients [25–27]. The high
TDRM prevalence seen in this study can indeed be explained by
revertants and other mutations, which have been shown to persist
over time after transmission and which, therefore, may also persist
during onward transmission in clusters [28,29].
In MSM we observed an increase of NNRTI TDRM and
decrease in protease inhibitor TDRM. This can be explained by
changes in therapies used over time in the Western world. NNRTI
are used in first line therapy in many patients and have a low
genetic barrier as development of resistance can occur with just a
single mutation [30]. Furthermore the use of non-boosted protease
inhibitors has decreased over time and selection of resistance to
boosted protease inhibitors is rare [31–34].
TDRM in IDU was found to be very low in Europe. An
explanation for this is the high proportion of IDU that are
originating from East and Central Europe. In many countries from
this region, the proportion of HIV-1 patients who receive therapy
is low and relatively slow increasing [35–37]. And even in
countries where the access to antiretroviral therapy is high, IDU
have lower rates of access [38–40]. The highest proportion of
resistance in IDU was seen for the NNRTI drug class. This might
also be due to the recent increase in access to antiretroviral
therapy in IDU. Therefore, this group did not experience the sub-
optimal NRTI therapy in the past, but have experienced the
increasing use of NNRTIs in Europe.
In this study, time trends for TDRM prevalence were analyzed
for MSM and heterosexuals using data from countries all over
Europe. Regions in Europe are dissimilar in HIV and TDRM
epidemics. For example, Eastern-, Central-, and Western Europe
differ in distribution of transmission groups [41], in (prior) access
to antiretrovirals [36] and in the size of their epidemic [41].
Therefore, TDRM differences between the HIV risk groups might
also be caused by the patients’ region of origin. However, region of
origin did not change the time trends, which suggest that the time
trend found in MSM and in heterosexuals are not caused by a
difference over time in the originating region of patients in
Europe.
A potential limitation of our study is the methodology used for
categorizing risk group, which was done through patient self-
reporting. This could lead to misreporting due to the urge to give
socially desirable answers. Discrimination can lead to fear of
disclosure of being MSM [42,43].
Another limitation of this study is that the data were collected
until 2007. As a consequence, the results may not be applicable to
the current situation in Europe. Although, we did not have access
to data from 2007 onwards, several studies from across Europe
confirm that after 2007, the prevalence of TDR remains the
highest among MSM [12,44]. We therefore believe that the
prevalence of TDR remains the highest among MSM.
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A strength of our study is the setting in which the SPREAD
programme is performed. The SPREAD programme is a large
and sufficiently powered pan- European study that has been
running since almost ten years. During this time the programme
included patients newly diagnosed with HIV using a predefined
strategy that is based on the risk group and geographical
distribution of HIV in the participating countries.
In conclusion, TDRM prevalence in MSM is high compared to
heterosexuals. A specific concern is the increase in NNRTI
resistance which increased three times within the study period of
five years. This increase is likely to negatively influence the therapy
response of first-line therapy, as most include NNRTI drugs.
Therefore, special attention is needed to the further development
of the prevalence of NNRTI TDRM in MSM patients.
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